Anebulo Pharmaceuticals (NASDAQ:ANEB) is a specialty pharmaceutical company focused on improving the delivery of small-molecule medications through its proprietary Intelligent Delivery Device, a wearable subcutaneous infusion system. The company’s primary goal is to shift therapies traditionally administered via intravenous infusion into a more patient-friendly subcutaneous format. By doing so, Anebulo aims to enhance drug safety, reduce the need for hospital resources, and enable broader use of established medications across acute and chronic care settings.
The company’s late-stage pipeline includes subcutaneous formulations of tramadol for acute pain management, ketamine for depression and complex pain conditions, and celecoxib for postoperative and chronic pain. Each candidate utilizes Anebulo’s infusion device to deliver precise, programmable dosing over an extended period, potentially reducing peak-to-trough variability and mitigating infusion-related complications. Anebulo is also exploring additional assets and indications that could benefit from its delivery platform, with the intent of building a diversified portfolio within hospital, outpatient infusion centers, and home infusion markets.
Founded in 2013 and headquartered in New York, Anebulo completed its initial public offering on the NASDAQ under the ticker ANEB in 2020. Since inception, the company has advanced its device through multiple design iterations, secured regulatory feedback, and established manufacturing partnerships to support clinical and commercial readiness. While its current activities are concentrated in the United States, Anebulo continues to evaluate collaboration and licensing opportunities to extend its reach into Europe and other international markets.
Under the leadership of President and Chief Executive Officer Don D. Moore, Anebulo maintains a management team with deep experience in medical devices, pharmaceutical development, and commercial operations. The executive team includes seasoned professionals in clinical development, quality and regulatory affairs, and business development, all committed to bringing the company’s innovative delivery solutions to patients and healthcare providers. Moving forward, Anebulo aims to secure regulatory approvals for its lead candidates and establish strategic partnerships to drive adoption of its subcutaneous infusion platform.
